A new treatment available this fall could keep infants and some older babies with RSV out of the hospital and even out of the doctor’s office.
Nirsevimab, brand name Beyfortus, was developed by AstraZeneca in collaboration with Sanofi, and was approved last month by the U.S. Food and Drug Administration. It’s a long-acting monoclonal antibody product administered as a shot. Monoclonal antibodies are man-made proteins similar to the antibodies humans naturally produce, which help the body fight off infection.
